XML 17 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Net sales $ 535,003 $ 508,745 $ 1,539,720 $ 1,496,719
Cost of goods sold 230,483 229,276 691,914 672,989
Gross profit 304,520 279,469 847,806 823,730
Selling, general and administrative expense 196,769 201,452 604,736 596,704
Research and Development Expense 61,372 49,924 173,483 148,321
Asset Impairment Charges 0 0 0 2,360
Segment profit (loss) 46,379 28,093 69,587 76,345
Interest expense 5,597 5,634 16,408 16,846
Foreign exchange losses, net 3,363 1,210 7,668 3,576
Other (income) expense, net (1,436) (1,439) (14,611) (13,824)
Income before income taxes 38,855 22,688 60,122 69,747
Provision for income taxes (11,462) (4,283) (15,281) (21,052)
Net income including noncontrolling interests     44,841 48,695
Net income attributable to Bio-Rad $ 27,393 $ 18,405 $ 44,841 $ 48,695
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 0.92 $ 0.63 $ 1.51 $ 1.66
Weighted average common shares - basic 29,660 29,444 29,618 29,402
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 0.91 $ 0.62 $ 1.49 $ 1.65
Weighted average common shares - diluted 30,052 29,671 29,994 29,592